French biotech lands man­u­fac­tur­ing deal in step to­ward com­mer­cial­iza­tion of rare bone dis­ease drug

As a start­up, it can some­times be tough to think too far ahead in the fu­ture. How­ev­er, with a ma­jor man­u­fac­tur­ing part­ner­ship an­nounced Wednes­day, CTO Ca­r­ole Schwint­ner and her team at MaaT Phar­ma are tak­ing the first steps to­ward es­tab­lish­ing a long-term game plan for the sev­en-year-old com­pa­ny.

The French biotech and CD­MO Skyephar­ma will part­ner to build the largest spe­cial­ized man­u­fac­tur­ing fa­cil­i­ty for mi­cro­bio­me-based ther­a­peu­tics. The plant will help MaaT in­crease its out­put by ten-fold by 2030, with the aim to pro­duce sev­er­al thou­sand en­e­mas of the lead can­di­date MaaT-013, to treat Graft-ver­sus-Host dis­ease (GvHD), which hap­pens when do­nat­ed bone mar­row or stem cells view the re­cip­i­ent’s body as for­eign, and do­nat­ed cells and bone mar­row at­tack the body. It will al­so pro­duce “sev­er­al hun­dreds of thou­sands cap­sules” of MaaT-033, for pa­tients who re­ceive an al­lo­gene­ic stem cell trans­plan­ta­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Recon Strategy

Boston, MA, USA